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Abstract
Background: Regulatory T cells (Treg) suppress cytotoxic T cell anti-tumoral immune responses and thereby
promote tumor progression. Prevention of intratumoral Treg accumulation by inhibition of their migration to the
tumor microenvironment is a promising therapeutic strategy. The aim of this study was to identify the role of the
two major Treg-attracting chemokines CCL1 and CCL22 in human breast cancer.
Methods: One hundred ninety-nine tissue samples of patients with invasive breast cancer were stained for CCL1
and CCL22 by immunohistochemistry. Chemokine expression and tumor infiltration by regulatory T cells,
determined by expression of the transcription factor FoxP3, were quantified and their correlation to clinical features
was statistically analyzed.
Results: Both CCL1 and CCL22 were expressed in most breast cancer tissues. CCL1 was significantly over-expressed
in invasive breast cancer as compared to normal breast tissue. CCL1, but surprisingly not CCL22, showed a
significant correlation with the number of tumor-infiltrating FoxP3+ Treg (p< 0.001). High numbers of intratumoral
CCL1 expressing cells were related to high grade tumors (G4) and a positive estrogen receptor (ER) status whereas
high CCL22 expression was generally seen in lower grade tumors. The median survival of 88 patients with high
intratumoral CCL1 expression was 37 months compared to 50 months for the 87 patients with low CCL1 levels, this
trend was however not statistically significant.
Conclusions: We found a high expression of CCL1 in human breast cancer. CCL1 significantly correlated with the
infiltration of immunosuppressive FoxP3+ Treg, that are known to negatively affect survival. Thus, CCL1 may serve
as prognostic marker and novel therapeutic target in breast cancer.
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Background
Breast cancer is the most frequent cancer in women
worldwide, currently affecting 12% of all women at one
time in their life [1]. It is a heterogeneous disease includ-
ing a wide range of biological behaviors and prognostic
characteristics [2]. During the last decades, early diagno-
sis and novel therapies helped to improve survival rate
in breast cancer [2]. However, current therapeutic ap-
proaches are still limited and breast cancer still accounts
for 14% of cancer-related mortality [3]. In the recent
years, with the emergence of checkpoint inhibitors and
the possibilities of engineered T cells, cancer immuno-
therapy has experienced a breakthrough in some tumor
entities [4]. Also in breast cancer, checkpoint inhibitors
are currently evaluated in several clinical trials and
might be effective in a subgroup of patients [5–8]. How-
ever, a close understanding of the tumor microenviron-
ment and its mechanistic is required to successfully
develop immunotherapeutic strategies in breast cancer.
Regulatory T cells (Treg) are a subtype of immunosup-
pressive CD4+ T cells that inhibit the cytotoxic function
of CD8+ T lymphocytes [9]. The physiological role of
Treg is to protect the body from autoimmunity by sup-
pressing self-reactive cells, including CD8+ cytotoxic T
cells, B cells and natural killer cells (NK cells) [10, 11].
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However, Treg also play an important role in cancer-associ-
ated immunosuppression [12]. The presence of Treg in
tumor, serum or lymph nodes of cancer patients is related
to poor survival in a variety of malignant diseases [13, 14].
In breast cancer, a strong infiltration with CD8+ cytotoxic T
lymphocytes has been reported to be associated with a fa-
vorable response to neoadjuvant chemotherapy and good
clinical outcome in breast cancer [15–17]. By contrast, a
high number of Treg has been associated to poor prognosis
in different types of breast cancer [18–20]. In order to pre-
vent Treg recruitment to tumor tissues, it is important to
identify the mechanisms of Treg attraction. One of the most
extensively described mechanisms of Treg attraction to
tumor sites is intratumoral expression of the chemokine
CCL22 [21].
CCL22 was found in several cancer types, often associated
with high infiltration of Treg and low survival [22–24]. Like-
wise, high expression of CCL22 in breast cancer is related to
a higher Treg infiltration and reduced prognosis [25]. An-
other more recently described chemokine that promotes
Treg de novo conversion and also Treg attraction to tumors
is CCL1 [26, 27]. It was shown that Sox2-mediated CCL1 ex-
pression in murine breast cancer models was related to a
higher infiltration by Treg and CCL1 overexpression led to
an increase of Treg accumulation [27]. To our knowledge,
CCL1 expression in human breast cancer tissues and its rela-
tion to Treg infiltration have not been described to date.
In order to determine the role of CCL1 and CCL22 on Treg
attraction to breast cancer, we analyzed 199 breast cancer tis-
sue samples that were previously stained [28] for expression of
CCL1, CCL22 and FoxP3. Chemokine expression and Treg
infiltration were statistically examined for their effects on pa-
tient survival. We found a significantly increased expression of
CCL1 in breast cancer tissues, which was related to a higher
infiltration of Treg. By contrast, expression of CCL22 was not
upregulated in tumor tissues compared to healthy breast tis-
sue and showed no impact on Treg infiltration. Our data
highlight the role of CCL1 on Treg migration into breast can-
cer tissue, a finding that might lead to novel therapeutic strat-
egies in breast cancer immunotherapy.
Methods
Tissue samples and patient characteristics
All tissue samples derived from female patients diagnosed
with mammary carcinoma at the Klinikum der Universität
München between 1986 and 2007 (n= 199). All patients
underwent surgical treatment of either mastectomy or wide
local excision with radiotherapy at the local gynecology unit
within 7months after diagnosis. Histological and molecular
characteristics of tumors were determined by the local Insti-
tute of Pathology according to the current WHO classifica-
tion. One hundred eighty of the tumors were classified as
ductal, 14 as lobular and 5 as unclassifiable. Non-malignant
control tissues were obtained from women that underwent
breast reduction surgery (n = 7).
Tissue microarray (TMA) and immunohistochemistry
A total of 7 TMA blocks containing 199 consecutive cases
were constructed by inserting cylindric tissue cores measur-
ing 2mm in diameter into a paraffin block. For each tumor
and non-malignant tissue 2 cores were embedded. Sections
of each TMA block were mounted on silane-coated slides
and subsequently further processed for immunohistochemis-
try as described before [29]. In short, antigen retrieval was
performed by 5min cooking in citric buffer (pH= 6.0). For
blocking ZytoChem Plus (HRP) Polymer Kit (Zytomed,
Berlin, Germany) was used according to manufacturer’s in-
structions. Primary antibodies against CCL22 (Peprotech,
Hamburg, Germany), FoxP3 (Abcam, Cambridge, USA) and
CCL1 (Atlas antibodies, Stockholm, Sweden) were incubated
for 16 h at 4 °C. Subsequent to 30min of incubation with a
horseradish peroxidase-polymer (Zytomed, Berlin, Germany)
staining was carried out using 3,3-diaminobenzidine-sub-
strate solution (DAB) (Dako, Glostrup, Denmark).
Statistical analysis
Stained slides were scanned with a high resolution scan-
ner MIRAX MIDI (Zeiss, Jena, Germany). CCL1- and
CCL22-positive cells (cytoplasmic staining) as well as
FoxP3-positive cells (nuclear staining) were counted in-
dependently by two observers (BK and IP).
To calculate the number of stained cells per mm2 the
area of each core was determined using ImageJ software
(V1.50i, NIH, USA). Of the 199 tumors on the array, 180
presented an assessable FoxP3 staining, 175 an assessable
CCL1 staining and 174 an assessable CCL22 staining.
The numbers of stained cells per mm2 were compared
between covariates using the Mann-Whitney-Wilcoxon
test. For correlations, the Spearman correlation coefficient
was used. Survival probabilities were estimated using the
Kaplan-Meier method and compared using the log-rank
test. Hazard ratios were derived from the Cox propor-
tional hazards model. P values below 0.05 were considered
significant. Due to the exploratory character of this work,
all p values have to be interpreted descriptively.
Ethics
The restrospectively registered study was approved by the
ethics committee of the Ludwig-Maximilians-Universität
München.
Results
High expression of CCL1 in invasive breast cancer
It is well established that high infiltration by FoxP3+ Treg
has an adverse effect on prognosis in breast cancer [30].
We have recently described expression of the classic
Treg-attracting chemokine CCL22 in breast cancers [31].
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CCL1 has been described to be expressed by breast cancer
stem cells and has been found to impact Treg migration in
murine breast cancer models [27, 32]. We therefore aimed
at analyzing the roles of the chemokines CCL1 and CCL22
in human invasive breast cancer. We stained tissue micro-
arrays (TMA) of 199 breast cancer patients for expression
of CCL1, CCL22 and FoxP3. We found CCL1, CCL22, and
FoxP3 expressing cells in most breast cancer tissues ana-
lyzed (Fig. 1a-c). Chemokine-expressing cells were pheno-
typically not identified as tumor cells but rather
tumor-associated immune cells (Fig. 1a-c). Strikingly, we
found significantly increased numbers of CCL1 and FoxP3
expressing cells in breast cancer tissues compared to nor-
mal breast tissues (Fig. 1d). Although CCL22 has been best
described in the context of Treg recruitment to cancer,
CCL22 levels were not significantly increased in our breast
cancer tissue cohort (Fig. 1d). Taken together, CCL1 ex-
pressing immune cells and FoxP3+ Treg are significantly
increased in invasive breast cancer tissues compared to
healthy breasts.
Intratumoral expression of CCL1 correlates to a higher
infiltration of FoxP3+ Treg
We next sought to evaluate possible associations between
chemokine and Treg infiltration. Strikingly, expression
levels of CCL1 showed a strong positive correlation with
Treg infiltration (Table 1). No significant correlation how-
ever was found between CCL22 expression and Treg num-
bers, indicating that CCL22 is not the major
Treg-attracting chemokine in breast cancer. Further, high
expression of CCL1 was related to negative ER status as
well as higher grade tumors (Table 2).
By contrast, higher expression of CCL22 was found in
lower grade tumors. Infiltration of Treg was significantly
stronger in high grade tumors and was correlated to nega-
tive ER status and positive Her2neu status.
As expected, high grade tumors showed a significantly in-
creased hazard ratio for mortality (1.45 vs. 1.0) (Table 3).
Altogether, our data suggest that an increased expression of
CCL1 is predominantly found in high grade tumors and is
related to infiltration by Treg.
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Fig. 1 CCL1 and FoxP3 are intensively expressed in human invasive breast cancer. Tissue microarrays (TMAs) of mammary carcinoma and non-
malignant control samples have been immunohistochemically stained for the indicated proteins. Representative sections for (a) CCL1, (b) CCL22
and (c) FoxP3 are shown. (d) TMAs of breast cancer and healthy breast tissue were analyzed for the number of positive cells/mm2. For statistical
analysis the Mann-Whitney-U-Test was used
Table 1 Correlation between chemokine expression and
density of FoxP3+ cells
Feature Correlation Coefficient p-value
CCL1 vs. FOXP3 0.42 < 0.001
CCL22 vs. FOXP3 0.07 0.360
Correlation coefficient between chemokine expression and FoxP3 expression
was analysed using the Spearman rank correlation coefficient
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Effect of intratumoral CCL1 and CCL22 on patient survival
We next analyzed the effect of CCL1 and CCL22 expression
on patients’ survival. The statistical follow-up period was 5
years. Expression of CCL22 showed no effect on survival
(data not shown). High expression of CCL1 showed some
association with poor survival (37months in CCL1 high vs.
50months in CCL1 low tumors), however the effect was not
statistically significant (HR= 1.1; 95% CI = 0.8–1.5) (Fig. 2).
Patients in both groups showed comparable clinical charac-
teristics in terms of UICC stage and age at diagnosis which
excluded a potential bias of heterogeneous clinical parame-
ters on the survival rate. UICC stage in the CCL1 high and
low group was 1% versus 7% of all patients classified stage I,
44% versus 39% stage II, 19% versus 13% stage III and 35%
versus 41% stage IV. The mean patients’ age at time of breast
cancer diagnosis was 53,6 years in the CCL1 high compared
to 52,8 years in the CCL1 low group respectively.
Thus, in breast cancer, CCL1 rather than CCL22
seems to impact Treg migration and could affect patient
survival.
Discussion
The unfavorable role of Treg in cancers has extensively
been demonstrated in the past decades, also in breast
cancer. Most publications show a detrimental role on
overall survival with high Treg numbers in breast cancer
tissues [19, 33]. In order to prevent Treg accumulation at
the tumor site, a profound knowledge of the mechanisms of
Treg migration is indispensable. In 2004, CCL22 was identi-
fied as a Treg attracting chemokine in ovarian cancer [21].
Since then, the role for CCL22 in attraction of CCR4+ Treg
to tumors was proven in numerous studies [25, 34, 35].
Other chemokines which have been associated with Treg
recruitment to tumors are CCL1, CCL5, CCL17, CCL20
and CCL28, acting on the chemokine receptors CCR4,
CCR5, CCR6, CCR8 and CCR10 [22, 36–38]. Amongst
these, CCL1 has been described to play a role on Treg de
novo conversion and Treg recruitment to murine breast
cancer models [32, 39]. CCL1 binds to CCR8, a receptor
that is known to be crucial for Treg function and prolifer-
ation [39]. In order to investigate the role of CCL1 and
CCL22 on Treg infiltration and overall survival in breast
cancer patients, we stained tissue microarrays of 199
breast cancer patients for the CCL1, CCL22 and FoxP3.
Surprisingly, our data showed upregulation of CCL1 in
breast cancer tissues, whereas CCL22 expression was not
elevated when compared to normal breast tissue and did
not correlate with Treg infiltration.
Chemokine expression and chemokine functions have
widely been studied in breast cancer. Chemokines with
well-known functions in mammary cancer include CCL2,
CCL5, CCL19, CCL20, CCL21 and CCL22 [40]. Their role
Table 2 Association between chemokine expression and pathological features
Feature CCL1 CCL22 FOXP3
Median p-value Median p-value Median p-value
ER-receptor – 12.8 0.029 3.1 0.128 18.0 < 0.001
+ 5.6 4.2 4.0
PR-receptor – 10.9 0.672 3.2 0.121 10.4 0.455
+ 9.0 4.0 8.0
HER2-receptor – 20.5 0.116 3.2 0.082 5.2 < 0.001
+ 45.2 4.6 23.1
Grading 2/3 5.1 0.010 6.2 0.006 4.0 < 0.001
4 12.8 2.8 17,5
Associations between chemokine or FoxP3 expression to histopathological features of the tumors, more precisely status of estrogen receptor (ER), progesterone
receptor (PR), Her2-receptor and tumor grading, have been analyzed by Mann-Whitney-Wilcoxon test
Table 3 Multivariate survival analysis for pathological features
Feature Hazard ratio 95% confidence interval p-value
ER-receptor – 1 0.580 to 1.254 0.419
+ 0.853
PR-receptor – 1 0.704 to 1.538 0.842
+ 1.041
HER2-receptor – 1 0.258 to 1.587 0.336
+ 0.640
Grading 2/3 1 1.049 to 1.993 0.024
4 vs. 2/3 1.446
Histopathological features have been analyzed by multivariate analysis with cox proportional hazards regression for mortality
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ranges from angiogenesis and metastasis to attraction of
various immune cell subtypes as macrophages, dendritic
cells and regulatory T cells [41–45]. By contrast, CCL1 is
known to activate Treg and promote FoxP3 expression, de
novo conversion and CCR8 expression on Treg [32, 39]. Its
role in shaping the tumor microenvironment was recently
demonstrated by the fact that CCL1 blockade in murine
breast cancer models led to reduced Treg numbers [32].
Moreover, phenotyping of human breast cancer infiltrating
Treg revealed high expression of CCR8 as compared to
peripheral blood Treg and CCR8 expression on intratu-
moral Treg had a negative impact on clinical outcome [46].
These data affirm our findings, which identify CCL1 as a
major component of the breast cancer immunosuppressive
machinery. The fact that high expression of CCL1 and
FoxP3 was found in high-grade tumors again suggests their
detrimental effect on prognosis, although we could not find
a significant effect on overall survival or tumor-free survival
in our analysis. We saw a correlation of CCL1 expression
to estrogen receptor status, which will be interesting to fol-
low up on in further studies. Considering the heterogeneity
of breast cancer, we believe that survival analysis will have
to be repeated in a bigger patient cohort, which will facili-
tate to account for the different breast cancer subtypes. A
more extensive analysis might thus unravel the role of
CCL1 mediated Treg recruitment on breast cancer patient
survival.
Conclusion
In summary, we identified CCL1 as a major Treg-attracting
chemokine in human invasive breast cancer. CCL1 was
highly upregulated in breast cancer, positively correlated
with Treg infiltration and high grade tumors, whereas none
of these was found for CCL22. We conclude that CCL1
might offer new interesting starting points for immunother-
apy in breast cancer.
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